Integrative Multi-Omics Deciphers the Antiepileptic Mechanism of Dingxian Pill — Based on the Interaction Between the SIRT2/Raf/ERK Pathway and the Microbiota-Gut-Brain Axis

This study deciphers the antiepileptic mechanism of the traditional compound Dingxian Pill (DXP), revealing a novel "gut-brain" dual-axis mode of action. We demonstrate that DXP alleviates temporal lobe epilepsy by simultaneously restoring gut microbiota homeostasis and directly inhibiting neuronal hyperexcitability. This study offers a promising therapeutic strategy for refractory epilepsy.
Fig 1 DXP indeed undergoes metabolism in mice and reaches the hippocampus to exert its effects.
Fig 2 Screening results of related targets for temporal lobe epilepsy
Fig 6 DXP treatment decrease RAF1 , phosphorylated RAF1-Ser473 , MEK1/2-Ser217/221 , ERK1-P-T202/Y204 and ERK2-P-T185/Y187 protein levels in the the Hippocampal.
Fig 7 Effects of DXP on the intestinal microbiome in temporal lobe epilepsy mice.
Fig 8 Effects of DXP on intestinal microbiome diversity in a mouse model of temporal lobe epilepsy
original Western blot images